AveXis Inc (NASDAQ:AVXS) had its target price increased by research analysts at Goldman Sachs Group Inc from $91.00 to $108.00 in a note issued to investors on Friday. The brokerage currently has a “buy” rating on the stock. Goldman Sachs Group Inc’s price target indicates a potential upside of 35.42% from the company’s current price.

Other equities analysts also recently issued reports about the stock. Chardan Capital restated a “buy” rating and set a $100.00 target price (up from $85.00) on shares of AveXis in a report on Tuesday, February 7th. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Tuesday, February 14th. Finally, BMO Capital Markets restated an “outperform” rating and set a $95.00 target price (up from $85.00) on shares of AveXis in a report on Friday. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.33.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) opened at 79.75 on Friday. The company’s market capitalization is $2.21 billion. The stock’s 50 day moving average is $62.69 and its 200-day moving average is $53.26. AveXis has a 12-month low of $20.51 and a 12-month high of $85.98.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, March 16th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by $0.12. During the same quarter in the prior year, the business posted ($1.82) EPS. On average, equities analysts predict that AveXis will post ($3.93) earnings per share for the current fiscal year.

Your IP Address:

A number of institutional investors have recently modified their holdings of AVXS. Pacad Investment Ltd. purchased a new position in shares of AveXis during the fourth quarter worth $277,000. A.R.T. Advisors LLC increased its position in shares of AveXis by 68.8% in the fourth quarter. A.R.T. Advisors LLC now owns 10,800 shares of the company’s stock worth $515,000 after buying an additional 4,400 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of AveXis during the fourth quarter worth $640,000. Norges Bank purchased a new position in shares of AveXis during the fourth quarter worth $1,193,000. Finally, GAM Holding AG purchased a new position in shares of AveXis during the third quarter worth $1,212,000. Institutional investors and hedge funds own 68.31% of the company’s stock.

About AveXis

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

5 Day Chart for NASDAQ:AVXS

Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.